Over the last 12 months, four Rein Therapeutics, Inc. corporate insiders bought shares at market prices, about $625,000 in total, and none of them sold.
Biggest single buyer: Voss Value-Oriented Special Situations Fund, LP, 10% Owner, with roughly $248,000.
No open-market insider buying or selling in the last full quarter. Insiders bought in 2 of the last 7 full quarters. 60 investment managers listed RNTX in their latest 13F filings (Q2 2026); more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| May 28, 2026 | VON RICKENBACH JOSEF H | Director | Buy | 4,500 | $1.07 | $5K | SEC |
| May 28, 2026 | VON RICKENBACH JOSEF H | Director | Buy | 23,190 | $1.06 | $25K | SEC |
| May 28, 2026 | VON RICKENBACH JOSEF H | Director | Buy | 15,950 | $1.05 | $17K | SEC |
| May 28, 2026 | VON RICKENBACH JOSEF H | Director | Buy | 3,420 | $1.04 | $4K | SEC |
| May 13, 2026 | WINDSOR JAMES BRIAN | Officer | Buy | 25,000 | $1.00 | $25K | SEC |
| Nov 18, 2025 | Voss Value Master Fund, LP | 10% Owner | Buy | 104,183 | $1.22 | $127K | SEC |
| Oct 28, 2025 | Voss Value-Oriented Special Situations Fund, LP | 10% Owner | Buy | 30,176 | $1.39 | $42K | SEC |
| Oct 28, 2025 | Voss Value-Oriented Special Situations Fund, LP | 10% Owner | Buy | 92,642 | $1.37 | $127K | SEC |
| Oct 28, 2025 | Voss Value-Oriented Special Situations Fund, LP | 10% Owner | Buy | 4,840 | $1.37 | $7K | SEC |
| Oct 28, 2025 | Voss Value-Oriented Special Situations Fund, LP | 10% Owner | Buy | 178,392 | $1.39 | $248K | SEC |
In the last 12 months Rein Therapeutics, Inc. insiders made open-market purchases worth about $625,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in RNTX was filed on 2026-05-28.
60 investment managers reported holding RNTX in SEC Form 13F filings for Q2 2026.
No congressional trades in RNTX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).